Karolinska appeared to be the Corporate Investor, which was created in 2003. The fund was located in Europe if to be more exact in Sweden. The main department of described Corporate Investor is located in the Solna.
Speaking about the real fund results, this Corporate Investor is 6 percentage points less often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2018. Comparing to the other companies, this Karolinska performs on 15 percentage points less the average number of lead investments. The fund is constantly included in less than 2 deals per year. The top amount of exits for fund were in 2019.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Karolinska, startups are often financed by btov Partners, Versant Ventures, Sectoral Asset Management. The meaningful sponsors for the fund in investment in the same round are HealthCap, Almi Invest, Vesalius Biocapital Partners. In the next rounds fund is usually obtained by Novartis Venture Fund, M Ventures, Vesalius Biocapital Partners.
Among the most popular portfolio startups of the fund, we may highlight NsGene, Promimic, OssDsign AB. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Clinical Trials, Health Care. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Sweden.
|Alfred Berg||Stockholm, Stockholm County, Sweden|
|Austria Wirtschaftsservice||Austria, Vienna|
|British Airways||England, London, United Kingdom|
|Chayuan Venture Capital||Beijing, Beijing, China|
|Ganexa Capital||Lisboa, Lisbon, Portugal|
|Iyogin Capital||Japan, Ota|
|Kunlun Capital||Central, Central Region, Singapore|
|Oxford Technology Management||Oxford, Oxfordshire, United Kingdom|
|PTT Public Company||Bangkok, Lat Yao Subdistrict, Thailand|
|Rising Tide Africa||-|
|Sangon Biotech||China, Shanghai|
|South Asia Growth Fund II (SAGFII)||-|
|Third Act Ventures||New York, New York, United States|
|TNN Capital||Luxembourg, Luxembourg|
|Vertex||King Of Prussia, Pennsylvania, United States|
|VILLAGEx||District of Columbia, United States, Washington|
|Xinhu Konggu||China, Hangzhou, Zhejiang|
|Zhonghuicheng Touzi||China, Guangdong Province, Longgang District|
|$72M||12 Sep 2022||Waltham, Massachusetts, United States|
|$8M||03 Jun 2022||Sweden, Skåne County, Sweden|
|$1M||12 May 2022||Stockholm, Stockholm County, Sweden|
|$3M||03 Feb 2022||Solna, Stockholms Lan, Sweden|
|17 Jun 2021||Solna, Stockholms Lan, Sweden|
|$59M||30 Nov 2018||Stockholm, Stockholm County, Sweden|
|$4M||05 Sep 2018||Southwest Finland|
|$2M||04 Oct 2017||Sweden, Stockholm County, Sweden|
|$3M||13 Sep 2016||Gothenburg, Västra Götaland County|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.